1. Show article details.

    Spectrum Pharmaceuticals to Present Corporate Update at the Bank of America Merrill Lynch 2016 Healthcare Conference on May 10th

    Business Wire – 7:00 AM ET 05/03/2016

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the Bank of America Merrill Lynch 2016 Healthcare Conference being held at the Encore at the Wynn in L...

  2. Show article details.

    Spectrum Pharmaceuticals Announces First Quarter 2016 Financial Results Teleconference and Webcast

    Business Wire – 7:00 AM ET 04/28/2016

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to discuss the first quarter 2016 financial results, provide an update on the Company's business, and discuss expectations for the future.

  3. Show article details.

    BRIEF-FDA grants orphan drug exclusivity to Spectrum Pharmaceutical's Evomela(tm)

    Reuters – 7:26 AM ET 04/20/2016

    Spectrum Pharmaceuticals Inc (SPPI) : * FDA grants orphan drug exclusivity to Evomela for injection, indicated for multiple myeloma. * Spectrum Pharmaceuticals Inc (SPPI) says Evomela has also been recently listed in orange book Source text for Eikon: Further company coverage:

  4. Show article details.

    FDA Grants Orphan Drug Exclusivity to EVOMELA™ (melphalan) for Injection, Indicated for Multiple Myeloma

    Business Wire – 7:00 AM ET 04/20/2016

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that the U.S. “We are pleased to receive FDA Orphan Drug Exclusivity for EVOMELA, another important regulatory milestone for Spectrum,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spect...

  5. Show article details.

    Ligand Partner Spectrum Pharmaceuticals Receives FDA Approval of EVOMELA™ (melphalan) for Injection

    Business Wire – 9:00 AM ET 03/15/2016

    Ligand to receive $6 million milestone related to EVOMELA’s approval Ligand Pharmaceuticals Incorporated (LGND) announces that Spectrum Pharmaceuticals, Inc. (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, received approval from the U.S. Food and Drug Administration of EVOMELA™ for use in two indications: 1)...

  6. Show article details.

    BRIEF-Spectrum Pharmaceuticals says FDA grants approval of Evomela for injection

    Reuters – 7:26 AM ET 03/15/2016

    Spectrum Pharmaceuticals Inc (SPPI). * FDA grants spectrum pharmaceuticals approval of Evomela for injection Source text for Eikon: Further company coverage:

  7. Show article details.

    FDA Grants Spectrum Pharmaceuticals Approval of EVOMELA™ (melphalan) for Injection

    Business Wire – 7:00 AM ET 03/15/2016

    HENDERSON, Nev. “I am very proud to announce that Spectrum has been able to bring another new cancer drug to the market,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals.

  8. Show article details.

    Spectrum Pharmaceuticals Reports Fourth Quarter 2015 and Full Year 2015 Financial Results and Pipeline Update

    Business Wire – 4:00 PM ET 03/09/2016

    HENDERSON, Nev. “We had solid operating performance this quarter and our pipeline has never been stronger with multiple drugs enrolling in late-stage trials,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals (SPPI). Pipeline Update: Three-Month Period Ended December 31, 2015 GAAP Results Total product sales were $34.8 million in the fourth quarter of 2015.

  9. Show article details.

    Spectrum Pharmaceuticals Initiates Phase 2 Breast Cancer Trial for Poziotinib, a Novel Pan-HER Inhibitor

    Business Wire – 7:00 AM ET 03/07/2016

    HENDERSON, Nev. “We believe Poziotinib has the potential to be the best in class pan-HER inhibitor,” said Rajesh C. Shrotriya, MD, Chairman and Chief Executive Officer of Spectrum Pharmaceuticals.

  10. Show article details.

    Spectrum Pharmaceuticals Announces Fourth Quarter and Full Year 2015 Financial Results Teleconference and Webcast

    Business Wire – 7:00 AM ET 03/02/2016

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a teleconference and webcast with management to discuss the fourth quarter and full year 2015 financial results, provide an update on the Company's business, and discuss expectations for the future.

  11. Show article details.

    Spectrum Pharmaceuticals to Present Corporate Update at 2016 RBC Capital Markets' Global Healthcare Conference on February 24

    Business Wire – 7:00 AM ET 02/22/2016

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the Company's business strategy and commercial and development-stage programs will be given at the RBC Capital Markets' Global Healthcare Conference being held at the New York Palace Hotel in New Y...

  12. Show article details.

    Labaton Sucharow LLP Announces Summary Notice Of Pendency Of Class Action, Proposed Settlement, And Motion For Attorneys' Fees And Expenses In In Re: Spectrum Pharmaceuticals, Inc., Securities Litigation

    PR Newswire – 9:00 AM ET 02/19/2016

    LAS VEGAS, Feb. 19, 2016 The following press release was issued today by LABATON SUCHAROW LLP: UNITED STATES DISTRICT COURT, DISTRICT OF NEVADAIn re: SPECTRUM PHARMACEUTICALS, INC. (SPPI), SECURITIES LITIGATIONCase No. 2:13-cv-00433-LDG TO: ALL PERSONS AND ENTITIES THAT PURCHASED OR ACQUIRED SPECTRUM PHARMACEUTICALS, INC. PUBLICLY TRADED COMMON STOCK AND/OR CALL OPTIONS, AND/OR SOLD PUBLICLY TRADED SP...

  13. Show article details.

    Spectrum Pharmaceuticals Announces FDA’s Acceptance of NDA Filing for EOquin® (apaziquone for intravesical instillation)

    Business Wire – 7:00 AM ET 02/19/2016

    Spectrum Pharmaceuticals (SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced that the U.S. Food and Drug Administration has accepted the EOquin® New Drug Application for review.

  14. Show article details.

    Investor Alert: Brower Piven Encourages Shareholders Who Have Losses in Excess of $100,000 From Investment in Spectrum Pharmaceuticals, Inc. to Contact Brower Piven Before the Lead Plaintiff Deadline in Class Action Lawsuit – SPPI

    GlobeNewswire – 6:24 PM ET 12/03/2015

    The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers of Spectrum Pharmaceuticals, Inc. (SPPI) securities during the period between May 7, 2015 and October 23, 2015, inclusive.

Page:

Today's and Upcoming Events

  • May
    5

    SPPI to announce Q1 earnings After Market (Confirmed)

  • May
    5

    SPPI Earnings Conference Call at 4:30 PM Listen

  • Jun
    28

    Shareholders Meeting

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2016

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.